Checkmate Pharmaceuticals Inc

NASDAQ:CMPI   11:42:56 AM EDT
2.40
-0.10 (-4.19%)
Regulatory, Other Pre-Announcement

Checkmate Pharmaceuticals Revises Guidance For Anticipated Timing Of Upcoming Data Milestones On Trials To Support Vidutolimod BLA Submission

Published: 12/14/2021 22:38 GMT
Checkmate Pharmaceuticals Inc (CMPI) - Checkmate Pharmaceuticals - Revised Guidance for Anticipated Timing of Upcoming Data Milestones on Trials to Support Vidutolimod Bla Submission.
Checkmate Pharmaceuticals - Sees Topline Data From Phase 2 Clinical Trial in Anti-pd-1 Refractory Melanoma Patients in H2 2023.
Checkmate Pharmaceuticals - Sees Data on Subset of Patients From Phase 2/3 Trial Evaluating Vidutolimod With Nivolumab Versus Nivolumab Alone in H2 2023.
Checkmate Pharmaceuticals - Changes Will Impact Timing of Co’s Anticipated Bla Submission for Anti-pd-1 Refractory Melanoma.
Checkmate Pharma - Shift in Anticipated Data Readout Timing Due to Slower Than Anticipated Patient Enrollment Attributable to Impact of Covid-19.
Further Company Coverage: Cmpio ((reuters.
Briefs@thomsonreuters.
Com;)).